Central Serous Chorioretinopathy
Conditions
Brief summary
Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy
Detailed description
Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. However, this treatment carries the risk of severe side effects. The goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.
Interventions
DRUGBrinzolamide Ophthalmic
Topical brinzolamide given bd for 3 months
Sponsors
Tel-Aviv Sourasky Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4 months of follow-up * Optical coherence tomography (OCT) shows foveal subretinal fluid * Fluorescein angiography and indocyanine green confirm the diagnosis
Exclusion criteria
* Any other ophthalmic condition that may lead to subretinal fluid * Choroidal neovascularization * Myopia \> -6D * Previous treatment for CSC in the past 6 months * Known allergy to fluorescein or indocyanin green * Known allergy for brinzolamide * Pregnancy, breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in subretinal fluid (microns) | 6 months | Change in subretinal fluid as measured by optical coherence tomography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in central macular thickness (microns) | 6 months | Change in central macular thickness in microns from baseline to last follow-up |
| Change in choroidal thickness (microns) | 6 months | Change in choroidal thickness in microns from baseline to last follow-up |
| Change in ETDRS visual acuity (number of letters) | 6 months | Change in visual acuity from baseline to last follow-up in ETDRS letters |
| Percentage of patients with fluid resolution | 6 months | Percentage of patients with fluid resolution by last follow-up as seen on optical coherence tomography, out of all study participants |
| Quality of life assessment (using NEI-VFQ-25 questionnaires) | 6 months | Quality of life score as assessed by standard questionnaires |
| Time for fluid resolution (days) | 6 months | Time in days from baseline until fluid resolution, as measured on optical coherence tomography |
Countries
Argentina, Israel
Contacts
Primary ContactDinah Zur, MD
Backup ContactRoy Schwartz, MD
Outcome results
None listed